1.gif (1892 bytes)

Personal Practice

Indian Pediatrics 2000;37: 1328-1340

Human Immunodeficiency Virus Infection


Surjit Singh

Correspondence to: Dr. Surjit Singh, Associate Professor of Pediatric Allergy & Immunology, Department of Pediatrics, Advanced Pediatric Center, Post Graduate Institute of Medical Education & Research, Chandigarh 160 012, India.
E-Mail : [email protected]

Infection with the Human Immuno-deficiency Virus (HIV) is now a major public health problem for both developing and developed countries as it has dramatically increased the global burden of disease. The devastating consequences of this pandemic would have health implications for the next many decades. Guestimates suggest that life expectancy at birth in some of the African countries which was just 44 years in the early 1950s and which had risen to as much as 59 years in the early 1990s, may again drop to near 45 years over the next decade or so because of the ill-effects of HIV infection and the acquired immunodeficiency syndrome (AIDS). The effects on children would be equally pathetic because it is believed that the accrued beneficial effects from all child health related programs may be anulled by HIV/AIDS(1-3).

According to data provided by UNAIDS, by end of 1999 the total number of people living with HIV/AIDS stood at 33.6 million of whom as many as 16 million were women and children below 15 years of age. The number of people newly infected with HIV in 1999 was 5.6 million of whom 2.3 million were women and 570,000 were children. About half of all people who acquire HIV infection do so before they turn 25 years of age and many of them die within the next 10 years or so, that is at a time when their economic productivity is at its peak. Many African countries have lost significant proportions of their workforce to HIV with grave conse-quences to the national exchequer(1).

It must be noted that while children can be ‘infected’ with HIV just as adults are, they can also be significantly ‘affected’ by HIV while remaining uninfected themselves. By the end of 1999, the pandemic had left behind a cumulative total of 11.2 million ‘AIDS orphans’ – a term used to identify children who have lost their mother to HIV/AIDS before the age of 15. Many of these maternal orphans have also lost their father. It is believed that more children have been orphaned because of HIV/AIDS than there are people who have developed AIDS. For every child who contracts the infection, the number ‘affected’ is at least 5 times higher(1-4).

It is unfortunate that HIV infection continues to be highly stigmatized in India. Children affected by or infected with HIV are discriminated against and often denied open access to health care. Majority of our hospitals do not have appropriate manage-ment protocols in place to look after the needs of such children. It is tragic, but nevertheless true, that many hospitals actually turn away HIV infected patients or deny them facilities which would be by right theirs had their HIV status not been known.

Health is not a priority area for many developing countries and the governments feel overwhelmed when faced with a crisis of such unprecedented proportions. However, if one goes by the experience of Brazil and Argentina (both of which can be termed as developing countries), provision of appro-priate counselling and treatment facilities (which include anti-retroviral drugs) is not only economically feasible within the constraints of their health budgets but also perhaps cost effective in the long run(5).

 HIV Infection in Children – How it is Different?

"A child is not a miniature adult" – this adage is as appropriate for HIV/AIDS as it is anywhere else. Unlike adults, where the primary route of transmission of HIV is sexual, majority of infected children acquire the disease from their mothers at the time of birth. In India, however, a small proportion (say 10-15%) of children continue to acquire the infection through transfusion of blood/blood products– this proportion is likely to fall down considerably over the next few years as blood bank screening procedures are further refined. Most perinatal transmissions occur at or near the time of birth which raises the theoretical possibility of initiating treatment in an infected infant from day one of life itself, provided the requisite diagnostic tests are available. In other words, it is possible to treat ‘primary’ HIV infection in children–a situation which is extremely difficult to define precisely in adults(6).

The perinatal transmission rates vary from 13-42% and are twice as high in Africa as in Europe(7). With the advent of use of anti-retroviral drugs in pregnant women with HIV, along with other measures, these rates would fall down considerably(8-13). A baby who has acquired the infection perinatally, poses considerable diagnostic problems for the physician because the usual laboratory tests (i.e., HIV IgG) are meaningless in view of the passive transfer of maternal IgG antibodies across the placenta.

The clinical behavior of HIV infection in children is also very different from that in adults. Children tend to have a more rapidly downhill course, have more of bacterial and less of opportunistic infections and tend to develop Kaposi’s sarcoma very rarely. Lypmphoid interstitial pneumonia (LIP) is characteristically seen only in children(14,15).

Monitoring of a pediatric patient while on anti-retroviral therapy (ART) is qualitatively very different from an adult. The CD-4 T-lymphocyte counts in infants are much higher (Table I) than in adults and show a progressive decline with age. The cut-off levels of CD4 T-lymphocytes for starting prophylactic therapy for opportunistic infec-tions are, therefore, considerably higher than adults(16-19).

HIV RNA levels in infants who are perinatally infected may often be higher than those observed in adults with HIV infection. Children may, therefore, take that much longer to show a comparable decline in RNA copy number(20-22). Further complete suppression of infection to a level where the viral RNA is undetectable is achieved much less often in children as compared to adults, inspite of being on equally potent triple drug regimens. The long term effects of ART are much less clearly defined in children.

In adults, it has been clearly shown that ART is more effective in treatment naive patients, as prior exposure to zidovudine or other nucleoside reverse transcriptase inhibitor (RTI) regimens may foster selection of drug resistant strains of the virus. A peculiar situation therefore arises in perinatally acquired infections where the fetus has been exposed to zidovudine and other antiretroviral drugs in the context of maternal treatment or prevention of perinatal transmis-sion. The therapeutic regimen selected for a given child should take these facts into consideration(4,23-26).

 Classification of Pediatric HIV Infection

A commonly used classification system is given in Tables I and II(4,27). A child should be labelled to have AIDS only in the presence of a precise defining illness/condition. Such conditions are often very difficult to define in the developing country set-up where the laboratory back-up may be totally inadequate. It may be noted that from the patient’s point of view this classification is to some extent only of academic interest because the decision to start specific ART is now not based on the precise categorization as it hitherto was. All infected children (and adults) should be offered ART irrespective of their symptom status or immunological dysfunction so as to preempt further deterioration(4).

 Laboratory Diagnosis

The laboratory diagnosis of HIV infection is based on identification of antibodies to viral proteins, detection of viral antigens, detection of viral nucleic acids or culture of the virus. The commonly used tests are as follows:

(i) HIV IgG elisa - is the usual screening test and detects IgG antibodies. Before declaring a patient to be seropositive, the test should be repeated using a different test principle (along with a rapid test) and only if all the tests so performed are positive should the patient be declared to have the infection. Babies below 18 months of age can have a passive transfer of IgG antibodies and may have false positive HIV ELISA. The currently available kits detect both HIV 1 and 2 and the sensitivity is over 99.5%. HIV IgG ELISA is the only test which is necessary for routine patient care in developing countries.

(ii) Western blot - detects antibodies to the various proteins and glycoproteins separated on an electrophoretic strip. Presence of antibodies to any two of the following antigen groups is taken as a positive test: p24, gp 41, gp 120/160. Western blots are prohibitively expen-sive and, in the developing country context, need not be done for routine diagnostic purposes.

(iii) HIV p24 antigen - detectable before the development of antibodies but has a rather poor sensitivity.

(iv) DNA PCR - amplifies proviral DNA and is an extremely sensitive method for early diagnosis of infection.

(v) Quantitative viral RNA - is a measure of the ‘viral load’ and is somewhat pre-dictive of the rate of CD 4 cell depletion. The test can be carried out using signal amplification (bDNA technology), target amplification (PCR) or nucleic acid sequence based amplification (NASBA). The test is expensive with each assay costing Rs. 8-10,000.

(vi) HIV culture - is cumbersome and diffi-cult to perform in most laboratories and the results are not available till at least 2-4 weeks.

In babies born to HIV seropositive mothers diagnostic tests ( p24 antigen, DNA PCR and HIV RNA assay) should be performed at 48 hours and at 2, 6 and 18 weeks. Early diagnosis is essential because identification of infection during the first few weeks of life allows the clinician to initiate ART or intensify the ongoing prophylactic regimen for prevention of perinatal trans-mission. Cord blood samples should never be used for diagnostic purposes because of the risk of contamination with maternal blood. An infant cannot be declared infected unless 2 of the 3 above mentioned tests are found to be positive on blood samples obtained at 2 different occasions(4,28-31).

 Monitoring of a Child with HIV Infection

Every child with HIV infection in whom ART is contemplated should be regularly followed up to look for any signs of clinical deterioration. Laboratory tests (CD4 counts and quantitative HIV RNA) should be performed regularly but are often difficult to carry out in our set-up because of the expenses involved. CD4 counts are age-dependent (Table I) and may decrease transiently following minor illnesses or after vaccinations(4,16-18). HIV RNA copy number is dependent on the assay method used with the inter-assay difference being as much as two fold (0.3 log 10). PCR based assays are more sensitive than bDNA based tests, but are technically more complex and less easily reproducble(4,19,32). Unlike adults, the predictive value of HIV RNA copy number with disease progression in children is less clearly established(4,33-35).

Table I - Pediatric HIV Infection – Immunological Categories based on CD4 Cell Numbers (4)

Immunological status <1 year 1-5 years 6-12 years
Category-1 (No immunosuppression) >=1500/
cu mm
>=25% >=1000/
cu mm
 >=25% >=500/
cu mm

>=25%

Category-2 (Moderate
immunosuppression)
750-1499/
cu mm
15-24% 500-999/
cu mm
15-24% 200-499/
cu mm
15-24%
Category-3 (Severe
immunosuppression)
<750/
cu mm
<15% <500/
cu mm
<15% <200/
cu mm
<15%

 

Table II - Revised Pediatric HIV Classification

Category N Not symptomatic
Category A Mildly symptomatic (i.e, children with 2 or more of the following conditions: lymphadenopathy, hepatomegaly, splenomegaly, dermatitis, parotitis, recurrent/persistent upper respiratory infection)
Category B Moderately symptomatic (e.g., anemia, neutropenia, pneumonia, oropharyngeal candidiasis, cardiomyopathy, lymphoid interstitial pneumonia, etc.)
Category C Severely symptomatic (i.e., children with any of conditions listed in the surveillance case definition for AIDS).

 Treatment of Pediatric HIV Infection

A. Principles

  1. All children with HIV infection should be offered specific ART irrespective of their clinical status, CD4 counts or HIV RNA copy number but economic feasibility is a major consideration in developing countries and only a minority of our patients are able to afford therapy.

  2. All drugs which have been approved for adults can be used in children even when specific pediatric pharmacokinetic studies have not been carried out and the effects on growth and development are not clearly defined.

  3. Monotherapy is contraindicated because it may result in incomplete suppression of HIV replication thereby allowing the emergence of drug resistance.

  4. Early initiation of appropriate therapy (hit hard, hit early!) is advantageous because it slows deterioration of immune function, delays progression of disease, reduces incidence of opportunistic infections and prolongs patient survival.

  5. ART is most effective in patients who have never received therapy (are treatment naive) and the most potent regimen, appropriate for a given clincial situation, should be initiated rather than keeping it ‘in reserve’ for future use.

  6. Treatment has to continue even after the CD4 T lymphocyte counts have reached normal levels and HIV RNA is undetectable in the blood. In such situations the virus can still be cultured from the lymph nodes and would result in a resurgence of the infection if ART is discontinued. Therapy, therefore, is a life-long commitment(2,4,24,36).

B. Drugs Available

A large number of anti-retroviral drugs are available to the clinician (Table III). HIV infection is now considered to be a ‘chronic manageable condition’ rather than a ‘rapidly fatal illness’. Prolonged survival is a distinct reality with the advent of triple drug therapy. Nucleoside analogue reverse transcriptase inhibitors (NRTIs) were the first drugs to be used for treatment of HIV infection and are also the least expensive. A combination of 2 NRTIs along with a protease inhibitor (PI) or a non-nucleoside analogue reverse trans-criptase inhibitor (NNRTI) is the preferred initial therapy. ddc is believed to be less powerful than ZDV, ddI or 3TC. ZDV and d4T should not be used together (Table III).

Table III - Available Drugs for Therapy

Drugs

Formulation Pediatric dosage Side-effects Comments
Nucloside Analogue RTIs
1. Zidovudine (AZT, ZDV) Syrup 50 mg/5 ml 
Cap. 100 mg
Tab. 300 mg
150 mg/m2/dose
QID
Anemia,
leukopenia,
myopathy
Should not be
given along
with d4T
2. Didanosine (ddI) Tab. 25-150 mg
Powder
120 mg/m2/dose
BD
Diarrhea,
peripheral
neuropathy
Should be given
on empty stomach
along with antacids
3. Zalcitabine (ddC) Tab 0.375-0.75 mg 0.01 mg/kg/dose
TDS
Peripheral
neuropathy,
pancreatitis
Should be given on empty stomach
4. Stavudine (d4T) SOL 5 mg/ 5ml
Cap. 15-40 mg
1 mg/kg/dose
BD
Peripheral
neuropathy,
pancreatitis
May result in
elevation of transaminases
5. Lamivudine (3TC)  Syrup 50 mg/5 ml 
Tab. 100, 150 mg
4 mg/kg/dose
BD
Headache,
pancreatitis
Prevents ZDV
resistance
6. Abacavir (ABC) SOL, 100 mg/5ml
Tab. 300 mg
8 mg/kg/dose
BD
Nausea,
headache
A serious
hypersensitivity
reaction can occur
Non-Nucleoside Analogue RTIs
1. Nevirapine (NVP) Susp. 50 mg/5 ml,
Tab . 200 mg
150 mg/m2/dose
BD
Skin rash, 
hepatitis
Rash usually
occurs within 6 weeks
2. Delavirdine (DLL) Tab. 100 mg Not known precisely Headache, rash Absorption decreased with antacids
3. Efavirenz (DMP-266) Cap. 50-200 mg Not known precisely Skin rash, Hallucinations Should be administered at bed-time
Protease Inhibitors
1. Ritonavir 400 mg/5 ml
Cap 100 mg
400 mg/m2/dose
BD
Nausea, pain abdominal, paresthesia Therapy should be initiated at a low dose
2. Indinavir Cap 200, 400 mg 500 mg/m2/dose
TDS
Nephrolithiasis,
hyperbilirubinemia
Ensure adequate hydration
3. Saquinavir Cap 200 mg
(Hard gel and soft gel)
Not known precisely Diarrhea,
hepatotoxicity
Should be administered 
with meals
4. Nelfinavir Poweder
Tab 250 mg
25 mg/kg/dose
TDS
Diarrhea, hepatotoxicity Should be adminstered with meals
5. Amprenavir Sol. 75 mg/5 ml
Cap 50, 150 mg
25 mg/kg/dose
BD
Nausea, rash,
paresthesia
Shold not be given with antacids

NNRTIs are being increasingly used in HIV treatment protocols even in children. Unlike most other anti-retroviral drugs, NNRTIs are not associated with significant side-effects and do not have restrictions associated with intake of food. Further they need to be taken only once or twice daily and this improves patient compliance. They also freely cross the blood brain barrier.

PIs have been in use for more than five years now. Nelfinavir and ritonavir were the first PIs to receive FDA approval for use in children. The major problems associated with PIs relate to the expense of therapy and poor patient compliance because of associated side-effects. Most PIs have restrictions related to intake of food and have significant drug-interactions, the most notable of these being with other anti-retroviral drugs and anti-tubercular medications(37). A number of disturbing and bizarre side-effects have recently been reported in patients on long-term therapy on this group of drugs. These include obesity (protease paunch!), lipo-dystrophy, gynecomastia, hyperglycemia, hyperlipidemia and perianal abscesses (tails!). It is these side-effects which preclude the continued use of PIs in upto 20-30% of patients(4,23).

C. What to Start?

Any one of the following combinations may be started:

  1. ZDV + 3TC + PI/NNRTI

  2. ZDV + ddI + PI/NNRTI

  3. d4T + 3TC + PI/NNRTI

  4. d4T + ddI + PI/NNRTI

We prefer using a combination of ZDV and 3TC. Other acceptable NRTI combina-tions include ZDV + ddI/ddC or d4T + 3TC/ddI. The role of dual PI based combinations (in addition to 2 NRTIs) as initial therapy is yet to be clearly defined, but may be considered in patients with advanced HIV disease. The only PI which is easily available in India is saquinavir but this is the least powerful of all the PIs.

D. When to Change

ART may need to be changed under the following circumstances:

  1. Clinical evidence of disease progression.

  2. Inadequate virological response even after 12 weeks of therapy from baseline HIV RNA levels; or repeated detection of HIV RNA in a child who had undetectable levels in response to initial therapy.

  3. Immunological deterioration, for example, a rapid/substantial decrease in CD4 counts.

  4. Failure of compliance with the current regimen.

E. What to Change to?

The striking short-term benefits of triple drug combination therapy should not preclude the fact that treatment is very expensive (Rs. 11,000 per month with a NNRTI based regimen and Rs.13,000 per month with a PI based regimen for an adult), therapeutic regimens are associated with lot of side-effects and the long-term efficacy (say beyond 3-5 years) is not clearly known.

Whenever a decision is made to change a given regimen, atleast 2 drugs (preferably all 3) should be replaced. While the NRTIs can be replaced by other drugs from the same class, the same does not hold true for the PI or NNRTI because of significant cross-resis-tance amongst other drugs of these classes. In effect, therefore, it means that a PI based regimen needs to be replaced with an NNRTI based regimen and vice-versa.

E. Is There a Role for Dual/Mono NRTI Therapy?

Theoretically, any child who requires ART should be given triple drug therapy. However, the cost of this therapy turns out to be prohibitive and very few of our patients are able to afford it. In such situations we do offer dual NRTI therapy (e.g., with ZDV and 3TC) as it results in significant clinical improve-ment and virological and immunological recovery and improves the overall quality of life, albeit for a short term. Development of resistance is a risk associated with such therapy but in children this is to some extent acceptable because under normal circum-stances children, unlike adults, would not pass on such resistant strains to other individuals. We never use monotherapy now a days(38-41).

F. Prevention of Perinatal Transmission

Prevention of perinatal transmission of HIV has been one of the big success stories of HIV treatment. In 1994 the joint French-American placebo controlled double blind trial (ACTG 076) of ZDV therapy showed that administration of the drug (100 mg five times a day) during the second and third trimesters of pregnancy followed by an intravenous bolus of 2 mg/kg at start of labour and 1 mg/kg/hour thereafter, and oral administration (2 mg/kg/every 6 hours) to the neonate for 6 weeks resulted in a 66% decrease in the rate of perinatal transmission if breastfeeding was not allowed. Subsequent trials conducted in Thailand (breastfeeding not allowed) and in Ivory Coast and Burkina Faso (breastfeeding allowed) have shown that even much shorter courses of ZDV (given for 2-4 weeks before delivery) have resulted in a significant decrease in rates of peri- natal transmission (by 38-50%). The cost of such short course ZDV regimens is obviously much less than the original ACTG 076 regimen. An even more promising regimen is the one pertaining to single dose nevira-pine (2 tablets of 200 mg each) along with a dose given to the newborn baby (2 mg/kg within 72 hours of birth), which resulted in a 50% reduction in perinatal transmission.

It is now clear that if in addition to administration of antiretroviral drug the mother undergoes an elective Cesarean section along with douching of the birth canal with virucidal agents, the perinatal trans-mission rates can be brought down to almost negligible levels (say 1-5%). This is indeed a big change from the perinatal transmission rates of 12-43% reported in early nineties(7-12,42-44).

G. Prophylactic Therapy

Prophylaxis against opportunistic infections is indicated whenever there is significant immunodeficiency. The most important opportunistic infection is with the fungus Pneumocystis carinii for which cotrimoxazole is the preferred drug and definite guidelines(4) are available for its use in children (Table III). The dose is approximately 1-2 mg/kg/day of trimethoprim given at bed-time. Cotrimoxazole perhaps also provides some protection against other bacterial infections which are common in developing countries. Rigid application of the guidelines for cotrimoxazole prophylaxis based on the child’s CD4 counts is difficult in our country because of the costs involved in performing the test.

Prophylaxis against Mycobacterium tuberculosis and fungal infections is given only when there is a specific indication (e.g., contact with an open case of tuberculosis; or culture proven systemic fungal infection). Routine use of isoniazid for all patients with HIV infection is not an acceptable clinical practice.

Table IV - Guidelines for PCP Prophylaxis for Children Born to HIV Seropositive Mothers(4)

Age Status of child Cotrimoxazole prophylaxis CD4 cell count monitoring
 1.  Birth - 6 weeks Born to HIV Seropositive mother Not required At birth & at 4-6 weeks
 2.  6 weeks - 4 months Born to HIV Seropositive mother Given to all babies Repeat at 3 months
 3.  4-12 months HIV infected or exact status not known Given to all such babies Repeat every 3 months
 4.  4-12 months HIV infection ruled out Stop prophylaxis Not required
 5.  1-5 years HIV infected Prophylaxis continued if child is in immune category 3 Repeat every 3 months
 6.  6-12 years HIV infected Prophylaxis continued if child is in immune category 3 Repeat every 3 months

H. General Care

Although majority of our children are unable to afford specific ART, there is still a lot that one can do for them. Incidental infections (e.g., pneumonia, diarrhea, pyo-derma) should be aggressively managed with appropriate antimicrobials. If the condition does not settle down, hospitalization may become necessary. Tuberculosis is especially common and may have unusual modes of presentation–the clinician, therefore, has to have a high index of suspicion.

We follow the usual immunization schedule in HIV infected children, but inactivated polio vaccine may be preferred to oral polio vaccine. The former, however, is not easily available in India. One should not unnecessarily withhold other live vaccines (e.g., BCG, measles) from such children because the accrued benefits far outweigh the associated risks, specially in developing countries. The immunodeficiency associated with HIV is quantitatively and qualitatively different from that of a child having severe combined immunodeficiency, a syndrome in which live vaccines are strictly contraindicated.

Nutritional rehabilitation is an important aspect of management of such children and requisite efforts must be put in to ensure an adequate intake of food items that are inexpensive and culturally acceptable. The results of such interventions are often very gratifying.

 Post-Exposure Prophylaxis

As the number of HIV infected patients increases it is inevitable that hospital accidents, due to needle-stick injuries and cuts with scalpels/other sharps involving hospital personnel who deal with them, would also show an increase. At our hospital we encounter 2-4 such accidents every year. The risk of seroconversion following a needle stick injury is believed to be 3/1000.

The site of exposure should be washed with water and detergent and a virucidal agent should be applied. All individuals who have had such accidental pricks/cuts or who have had mucocutaneous exposure to biological fluids (say over the conjunctiva) should be offered counselling and advised to take a course of ZDV and 3TC for at least 4 weeks, preferably longer. Further, an ELISA test should be performed soon after exposure and repeated thereafter at 6 weeks and 6 months. In situations where the chances of transmission are very high (e.g., patient with high viral load and inoculation involving a hollow bevelled needle) indinavir should be administered along with ZDV and 3TC.

Needless to say such accidents are best prevented. One must incorporate stringent precautions (universal precautions) in day to day clinical care. All biological samples must be considered potentially infected. Gloves should be worn during venepunctures and while setting up drips. We use bleaching powder for disinfection of soiled bandages, bed linen, etc.

 Newer Drugs

Triple drug therapy is by no means a panacea as far as treatment of HIV infection is concerned. There is a significant number of patients (say 20-40%) who have to dis-continue such therapy due to intolerable side-effects (specially with PIs), treatment related toxicity or treatment failure. A number of new approaches are being tried in such situations. These include use of integrase inhibitors (e.g., AR 177) and fusion inhibitors (e.g., T-20). The latter group of drugs prevent fusion of HIV with target cells. Adefovir, a nucleotide analogue, has also shown promising results and is believed to be unique because HIV does not easily develop resistance to it.

Even amongst the conventional groups of AR drugs, exciting developments are taking place. Newer NRTIs (e.g., emtricitabine), NNRTIs (DMP 961, DMP 963, AG 1549) and PIs (e.g., AG 1776, ABT 378) are in the stage of trials and may turn out to be clinically useful.

Further, chemokines have been isolated which interfere with co-receptors involved in HIV infection (e.g., CCR5, CXCR4). Benz-amide comopunds interfere with zinc finger proteins which are necessary for viral packaging and replication.

Although curative therapy of HIV infection is still a distant mirage, overall there is far more optimism today than was the case in early nineties.

 Sources of Information

Treatment guidelines for HIV are changing rapidly and regimens which are state of the art today may be considered obsolete within a year. A number of websites are available which provide regular updates. These include http://www.aegis.com/; http://www.aegis.com/areas.html; http://www.tele port.com/celinec/aids.shtml; http://www.crit papth.org/aric; http://www.hivatis.org; http://www.bcpwa.org; http://www.aidsnyc.org/nat.ap; http://www.catie.ca; http://www.aidsnyc.org/network; and http://www.jri.org/infoweb/treatment/library/beta.

Key Messages

  • A number of highly effective anti-retroviral drugs are now available for treatment of Human Immunodeficiency Virus (HIV) infection, even in children.

  • HIV infection is no longer considered a rapidly fatal illness, but rather a chronic manageable condition.

  • Although specific antri-retroviral therapy is rather expensive at present and beyond the reach of many patients in developing countries, there is a lot else that one can do for management of such children.

  References
  1. AIDS Epidemic Update, December 1999. UNAIDS/WHO, Geneva, 1999.

  2. Scarlatti G. Pediatric HIV infection. Lancet 1996; 348: 863-868.

  3. Graham WJ, Newell ML. Seizing the oppoutunity: Collaborative initiatives to reduce HIV and maternal mortality. Lancet 1999; 353: 836-839.

  4. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Convened by National Pediatric and Family HIV Resource Centre, the Health Resources and Services Administration and the National Institute of Health, January 7, 2000.

  5. Hourcade Bellocq JL, Talavera J. Great involvement of PWAs in AIDS services organizations as policy and as strategy. From the Global Network of People Living with HIV/AIDS Latin American Secretariat, Buenos Aires, Argentina, (Abstract 0182). Proceedings of the 3rd International Conference on Home and Community Care for Persons living with HIV/AIDS, May 1997.

  6. Writing Committee of the Perinatal HIV Intervention Research in Developing Countries Workshop. Science, ethics, and the future of research into maternal infant transmission of HIV-1. Lancet 1999; 353: 832-835.

  7. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet 1992; 339: 1007-1012.

  8. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott. G, O’Sullivan MJ, et al. Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-1180.

  9. Shaffer N, Chauachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomized controlled trial. Lancet 1999; 353: 773-780.

  10. Wiktors S, Ekpim E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire: A randomized trial. Lancet 1999; 353: 781-785.

  11. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: A double-blind placebo controlled multicentre trial. Lancet 1999; 353: 786-792.

  12. Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG et al. Cost effectiveness of single-dose nevirapine regi-men for mothers and babies to decrease vertical HIV-1 transmission in sub-saharan Africa. Lancet 1999; 354: 803-809.

  13. Centers for Disease Control and Prevention. Public Health Service Task Force Recom-mendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR 1998; 47 (no. RR-2).

  14. Blanche S, Newell M-L, Mayauz M-J, Dunn TT, Teglas JP, Rouzioux C, et al. Morbidity and mortality in European children vertically infected by HIV-1: The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retroviral 1997; 14: 442-450.

  15. Barnhart HX, Caldwell MB, Thomas P, Mascola L, Ortiz I, Hsu HW, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: An analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996; 97: 710-716.

  16. Conley ME, Stiehm ER. Immunodeficiency Disorders: General Considerations. In: Immunologic Disorders in Infants and Children, 4th edn Ed Stiehm ER. Phila-delphia, W.B. Saunders Co., pp 201-252.

  17. European Collaborative Study. Age-related standards for T lymphocyte subsets based on uninfected children born to Human Immunodeficiency Virus-1 infected women, Pediatr Infect Dis J 1992; 11: 1018-1026.

  18. Comans-Bitter WM, de Groot R, Van den Beemd R, Neijens. JH, Hop WC, Groeneveld K, et al. Immunophenotyping of blood lymphocytes in childhood: Reference values for lymphocyte subpopulations. J Pediatr 1997; 130: 338-393.

  19. Mellors JW, Munoz A, Giorge JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.

  20. Goetz MB, Moatamed F, Hawanitz JH. Measurement of plasma HIV viral load (VL) by bDNA versus RT PCR assays. Clin Infect Dis 1997; 25: 394 (Abstract).

  21. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.

  22. Hughes MD, Johnson VA, Hirsch MS, Brenner JW, Elbeik T, Erice A, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4 + lymphocyte count improves assessment of antiretroviral thera-peutic response. Ann Intern Med 1997; 126: 929-938.

  23. Lipsky JJ. Antiretroviral drugs for AIDS. Lancet 1996; 348: 800-803.

  24. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, et al. Combination treatment with zidovudine, didovudine, didanosine and nevirapine in infants with Human Immunodeficiency Virus type-1 infection. N Engl J Med 1997; 336: 1343-1349.

  25. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic milimeter. N Engl J Med 1997; 336: 1091-1098.

  26. Englund JA, Backer CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, et al. Zidovidine, didanosine, or both as the initial symptomatic HIV-infected children. N Engl J Med 1997; 336: 1704-1712.

  27. Cherry JF, Feigin RD. Infection in the compromized host. In: Immunologic Dis-orders in Infants and Children. 4th edn. Ed. Stiehm ER. Philadelphia, W.B. Saunders Co., pp 991-995.

  28. Palumbo PE, Kwok SH, Waters S, Wesley Y, Lewis D, McKinney N, et al. Viral measure-ment by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr 1995; 126: 529-553.

  29. Shearer WT, Quinn TC, La Russa P, Lew JF, Mofenson L, Almy S, et al. Viral load and disease progression in infants with human immunodeficiency virus type-1. N Engl J Med 1997; 336: 1337-1342.

  30. Dickover RE, Dillon M, Gillette SG, Deveikis A, Keller M, Plaeger-Marshall S, et al. Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants. J Infect Dis 1994; 170: 1279-1284.

  31. McIntosh K, Pitt J, Brambilla. D, Kornegay J, Chatis P, Karthas N, et al. Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immuno-deficiency virus infection. J Infect Dis 1994; 170: 996-1000.

  32. Vandamme A-M, Schmit J-C, Van Dooren S, Van Laethem K, Gobbers E, Kok W, et al. Quantitation of HIV-1 RNA in plasma: Comparable results with the NASBA HIV-1 RNA QT and the Amplicor HIV Monitor test. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 127-139.

  33. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, et al. Disease progression in HIV-infected infants and children: Predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count. JAMA 1998; 279: 756-761.

  34. O‘Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both responses to antiviral therapy and therapeutic failure. Ann Intern Med 1997; 126: 939-945.

  35. Mofenson LM, Korelitz J, Meyer WA, Bethel J, Rick K, Pahwa S, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte per cent, and long term mortality risk in HIV-1 infected children. J Infect Dis 1997; 175: 1029-1038.

  36. Ruiz L, van Lunzen J, Arno A, Stellbrink JH, Schneider C, Rull M, et al. Protease inhibitor-containing regimens compared with mucleo-side analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13: F1-F8.

  37. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 685-693.

  38. Kline MW, Van Dyke RB, Lindsey JC. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. Pediatrics 1998; 101: 241-220.

  39. Lewis LL, Venzon D, Church J, Farley M, Wheeler S, Keller A, et al. Lamivudine in children with human immunodeficiency virus infection: A phase I/II study. J Infect Dis 1996; 174: 16-25.

  40. Kline MW, Dunkle LM, Church JA, Goldsmith JC, Harris AT, Federici ME, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995; 96: 247-252.

  41. Butler KM, Husson RN, Balis FM. Dideoxy-inosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 324: 137-144.

  42. American Academy of Pediatrics, Provisional Committee on Pediatric AIDS. Perinatal human immunodeficiency virus testing. Pediatrics 1995; 95: 303-307.

  43. McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, Karthas N, et al. Age and time related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996, 15: 1087-1091.

  44. Mayauz M-J, Burgard M, Teglas-J-P. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. JAMA 1996; 275: 606-610.

Home

Past Issue

About IP

About IAP

Feedback

Links

 Author Info.

  Subscription